devinitorg/iati-policy-markers huggingface dataset:
Proposal and Partnership Development Awards (PPDA) for NIHR Research and Innovation for Global Health Transformation (RIGHT) call 5 Stage 2 applicants The purpose of Proposal and Partnership Development Awards (PPDA) funding is to improve the quality and likelihood of success of the projects funded through the NIHR Research and Innovation for Global Health Transformation (RIGHT) programme. Applicants that are successful at RIGHT Stage 1 and invited to submit a Stage 2 application are eligible for a PPDA, subject to satisfactory submission of a PPDA application. Not all Stage 2 applicants awarded a PPDA go on to secure RIGHT programme funding. For RIGHT Call 5, PPDA were extended to 12 applicant organisations to support partnership development and the preparation of a RIGHT Stage 2 application. Proposal and Partnership Development Awards (PPDA) provide funding of up to £10,000 for organisations applying to NIHR Research and Innovation for Global Health Transformation (RIGHT) programme funding to:
1.	Support applicants to work collaboratively with all study partners to develop the stage 2 application
2.	Enhance partnerships across the proposed research collaboration
3.	Initiate preparation of study governance documentation (i.e. due diligence and finance assurance policies)
PPDA funds must be spent between the notification of RIGHT stage 1 outcome and the submission of the RIGHT stage 2 application.
NIHR Global Health Research Group on Early Childhood Development for Peacebuilding A UK and low- and middle-income country (LMIC) partnership that aims to support the implementation and  evaluation of early childhood development programmes and the potential to promote sustainable development and peacebuilding in LMICs affected by conflict. This research has the direct and primary aim of improving the health, wellbeing and economic development of people in LMICs. 1) To create a sustainable network of early childhood development (ECD) researchers and practitioners from six countries affected by conflict. 2) To share knowledge and expertise across participants of the network and build research capacity in country to support the development and robust evaluation of ECD programmes. 3) To build specialist research capacity at Centre for Evidence and Social Innovation (CESI) to undertake global health research in relation to ECD,through the support of Yale and NYU. 4) To support the evaluation of ECD pilot programmes in six LMIC partner count ries that are to be delivered through support from UNICEF. 5) Work with UNICEF and the wider global Early Childhood Peace Consortium (ECPC) to develop and implement effective advocacy strategies for ECD programmes within partner countries and internationally. 6) Develop and implement a strategy to generate external funding to sustain and grow the network beyond the current three-year funding window in alignment with ECPC.
NIHR Global Health Research Group on Estimating the Prevalence, Quality of Life, Economic and Societal Impact of Arthritis in Tanzania A UK and low- and middle-income country (LMIC) partnership that aims to establish a centre of excellence in Tanzania in social science research to understand the distribution and impact of arthritis in Tanzania and inform prevention and intervention plans. 1) Establish new research collaborations between Universities of Glasgow/Newcastle and Kilimanjaro Clincial Research Institute. 2) Understand and describe the lived experience of joint pain and arthritis in Tanzania. 3) Describe how the ‘arthritis and joint pain’ problem is managed in clinical settings. 4) Estimate the prevalence of the main forms of arthritis in community settings in Tanzania. 5) Identify existing evidence on arthritis quality of life, health seeking behaviour and resource utilisation and pilot instruments.  6) Increase training and capacity building in social science in Tanzania.
Following a costed extension, additional objectives will include:

Study 1: Evaluate a new rheumatology clinic through documenting and evaluating the process by which the clinic is established, who is referred, how patients are identified and managed, and short-term outcomes.
1. Describe the socio-demographics, clinical characteristics and short-term outcomes of patients.
2. Evaluate the processes through which the clinic is established and identify future directions.

Study 2: Identify culturally relevant attributes of capacity wellbeing by building directly on initial qualitative findings.
1. Conduct formative qualitative research to inform the development of a future instrument for intervention evaluation research into non-communicable diseases.
European and Developing Countries Clinical Trials Partnership (EDCTP) phase III The UK Department of Health and Social Care (DHSC) funds outstanding global health research through the National Institute for Health and Care Research (NIHR). The NIHR provides funding to the Global Health European and Developing Countries Clinical Trials Partnership 3 (Global Health EDCTP3) Joint Undertaking which works to deliver new solutions to reduce the burden of poverty-related infectious diseases in sub-Saharan Africa and to strengthen research capacities to prepare and respond to re-emerging infectious diseases. Global Health EDCTP3 builds on EDCTP Phase 2, which NIHR has been contributing to since 2016 (GB-GOV-10-EDCTP2). As EDCTP transitions to Global Health EDCTP3, calls under the new work packages will support further clinical research and training in sub-Saharan Africa. The EU Strategic Research and Innovation Agenda (SRIA) for the Global Health EDCTP3 programme has two programmatic aims and five specific objectives for the 2021 to 2031 work programme. The programme aims to: (1) reduce the individual, social, and economic burdens of infectious diseases in sub-Saharan Africa through the development and uptake of new or improved interventions and (2) increase health security in sub-Saharan Africa and globally, particularly in the context of environmental change and the climate crisis, by reducing the risk of outbreaks and pandemics, and enhancing national and regional capacity to address antimicrobial resistance. Five specific objectives: 1) Advance biomedical interventions towards improved overall health, 2) Research capacity development, 3) Enhance coordination, 4) Strengthen capacity for epidemic preparedness and 5) build partnerships and strategic alliances.
Global Antibiotic Research and Development Partnership’s Neonatal Sepsis Programme (GARDP) support A partnership to fund the development of new treatments for severe bacterial infections in neonates under GARDP’s Neonatal Sepsis Programme The overall purpose of GARDP’s neonatal sepsis programme is to develop up to three new or improved treatments for newborns with severe bacterial infections by 2023. The activities funded under this programme will make an important contribution towards achieving these objectives by prioritising three work packages with the following focus:
1. Improve clinical management of neonatal sepsis
This work package includes three key activities: completion of the global observational study; commencing clinical programme to develop a treatment to be used in place of the current WHO recommended empiric treatment, ampicillin and gentamicin for neonatal sepsis, and conducting clinical and laboratory capability strengthening in support of the clinical programme.
2. Developing new and improved treatments for multi drug-resistant infections in neonates
This work package will aim to develop an effective and safe treatment for confirmed or highly suspected MDR-GN pathogens, including K. pneumoniae, or Acinetobacter spp., that is affordable and adapted for use in neonates.
3. Accelerating regulatory approval and access in high burden LMICs
Through this work package, GARDP will work with WHO, pharmaceutical companies and regulatory authorities to ensure the newly developed treatments are globally accessible and that they are not ‘lost’ to resistance within a few years after their introduction. To achieve this, GARDP, in partnership with the relevant partner(s), will develop regulatory, public health and market access (including supply and distribution) strategies for any treatments developed.
NIHR Global Health Research Unit on Tackling Infections to Benefit Africa (TIBA) A UK and low- and middle-income country (LMIC) partnership that aims to reduce the burden of infectious diseases by strengthening health systems in Africa. This research has the direct and primary aim of improving the health, wellbeing and economic development of people in LMICs. 1) Improve the diagnosis and surveillance of infectious diseases in resource-poor settings.  2) Improve the deployment of existing drug treatments and enhance local capacity to develop new ones. 3) Improve the management of both endemic and emerging infections by strengthening health systems, with special attention to ethics and governance; improving policy development and implementation (e.g. drug procurement, local licensing, regulatory harmonization); and enhancing capacity to respond to infectious diseases emergencies, while protecting capacity to manage endemic diseases concurrently.
European and Developing Countries Clinical Trials Partnership (EDCTP) phase II: WHO support for World Health Assembly Clinical Trials Resolution The UK Department of Health and Social Care (DHSC) funds outstanding global health research through the National Institute for Health and Care Research (NIHR). The NIHR provided funding to European and Developing Countries Clinical Trials Partnership (EDCTP) which aims to support collaborative research that accelerates the clinical development of new or improved interventions to prevent or treat poverty related as well as emerging and re-emerging infectious diseases affecting sub-Saharan Africa. NIHR has supported through EDCTP2 proposed actions for WHO to support implementation of the World Health Assembly Clinical Trials Resolution. This activity is a component of European and Developing Countries Clinical Trials Partnership (EDCTP) phase II programme (GB-GOV-10-EDCTP2). Support to WHO to develop global normative implementation guidance to focus clinical trials on key design features that will increase the quality of evidence for decision-making and increase trial capacity, particularly focussed on low and middle-income country settings, as part of implementaion of the World Health Assembly Resolution on Clinical Trials (WAH 75.8).
NIHR RIGHT 5: Early warning of mosquito-borne disease outbreaks caused by extreme weather in Uganda A UK and low-and-middle-income-country (LMIC) partnership between the Malaria Consortium and Uganda Virus Research Institute that aims to improve the health system in Uganda to develop a capacity to forecast impending outbreaks of mosquito-borne diseases associated with extreme weather events.

Commencing in January 2024, the four-year research will be implemented in three phases:

Phase one involves the analysis of data on past outbreaks to determine associations with extreme weather events and other factors. Past data on disease incidence, weather variables, and other risk indicators will be used to develop forecasting models.

Phase two, involves the development of an interactive risk mapping platform based on the forecasting models and data inputs for routine use. The mapping approach will be based on a dashboard portal developed within the research partnership.

Phase three consists of developing a national outbreak preparedness and response plan which will be based on existing plans in close collaboration with all relevant partners. The plan will be aligned with outputs of the online portal to provide specific guidance on interventions.

Affected communities, local health services, and village health workers will be engaged to identify important risk factors and gaps in outbreak preparedness. The researchers will be working closely with government and other partners for adoption and routine use of the system and the associated plan for prevention of outbreaks and effective mitigation of their impacts. The project has six objectives:

1. To document past mosquito-borne disease outbreaks in Uganda and analyse their association with extreme weather.

2. To develop and validate a risk index and early warning models to forecast the outbreaks.

3. To develop a platform that maps risks and generates predictions continuously, with real-time surveillance data feeding into it, for routine use by disease control programmes.

4. To develop an outbreak preparedness and response plan for various risk scenarios.

5. To facilitate adoption and use of the outbreak risk mapping system. 

6. To engage communities across the research activities.
Research to Improve Adolescent Health in Low- and Middle-Income Country (LMIC) Settings: call 3 This programme is administered by the UK Medical Research Council (MRC), which reports activities under the UK Department for Business, Energy and Industrial Strategy (BEIS). NIHR disburses funds to MRC, which makes onwards disbursements to awardees. This initiative funds research grants to improve adolescent health in low- and middle-income countries (LMICs). Overall this call will support high-quality, applied research answering questions of effectiveness and access that will result in improved adolescent health in LMICs. Sub-objectives include:
1 ) Fund high-quality research to address major health issues that emerge at the adolescent phase of life;
2) Provide the research evidence needed to effect real and practical changes to improve adolescent health in Low- and Middle-Income Countries (LMICs);
3) Encourage genuine interdisciplinary collaborations across social science, biomedical science and other disciplines including health economics and political science;
4) Support capacity building in research
NIHR RIGHT3: Multimorbidity of HIV and severe acute malnutrition in sub-Saharan Africa A UK and low-and-middle-income-country (LMIC) partnership that aims to improve the recovery of children with human immunodeficiency virus (HIV) infection and severe acute malnutrition (SAM) after they leave hospital by tackling underlying medical and social causes of ill-health. Two networks of researchers with expertise in child health, mental health, laboratory science, social science and health economics, based in southern Africa (Zimbabwe and Zambia) and east Africa (Kenya), together with partner institutions in the UK, USA and Netherlands, will come together to undertake this project between 01-09-2021 and 31-08-2025. The goal is to better understand why children with HIV and SAM have a higher risk of dying and a lower chance of long-term recovery compared to children with SAM alone. The partnership plans to develop packages of interventions to ensure that children with HIV and SAM can survive and thrive. 1: To understand the ‘multimorbidity’ of with human immunodeficiency virus (HIV) and severe acute malnutrition (SAM).
2: To develop packages of interventions that will help children with HIV and SAM to recover more effectively when they leave hospital. 
3: To conduct a clinical trial which compares the new treatments (singly or in combination) against the best current treatment which is therapeutic food, anti-HIV drugs and an antibiotic called cotrimoxazole.
NIHR RIGHT2: Care for perinatal depression through enhancements to the ‘Thinking Healthy Programme’ A UK and low- and middle-income country (LMIC) research partnership that aims to scale-up care for Perinatal Depression in Pakistan, Nepal, Bangladesh and Sri Lanka, through development of technology to support lay-therapists to deliver a World Health Organization (WHO)-approved Cognitive Therapy based intervention. The project aims to develop knowledge and tools to improve management of perinatal depression in women in four South Asian countries (Pakistan, Nepal, Bangladesh and Sri Lanka). Perinatal depression affects about one in four women in South Asia and has huge human and economic costs. It can be treated effectively with talking therapies. However, the vast majority of women in low-income countries remain untreated because of overburdened health systems and lack of mental-health specialists. The project focuses on use of technology to enable local lay-therapists to deliver an established talking therapy. If successful the technology would facilitate task-shifting the delivery of the therapy from a few specialists in overburdened health systems to appropriately trained lay-persons, thereby increasing the number of care providers and improving opportunities for women to access treatment.  
The objectives of the work are:  
1. Develop and evaluate a digital Application (App) to facilitate delivery of a WHO-approved talking therapy, the “Thinking Healthy Programme”, by lay-women in Pakistan.   
2. Improve implementation research capacity in four South Asian countries, Pakistan, Nepal, Bangladesh and Sri Lanka, to facilitate scale-up of the intervention in their settings.
NIHR RIGHT 5: A Novel Extreme Weather Risk Insurance System for Kenya (NEWRISK) A UK and low-and-middle-income-country (LMIC) partnership which aims to investigate the best ways to protect Kenya’s health system from the effects of extreme weather. Currently, lower middle income countries like Kenya face significant health impacts from extreme weather, but do not have plans in place to protect their vulnerable populations.

Beginning in January 2024, Oxford University will work with Kenyan partners over four years to address this issue by developing high resolution climate models that show how anticipated changes to Kenya’s climate and impacts on the country’s health facilities. The team will map vulnerable populations and survey health facilities in order to determine how extreme weather will impact access to healthcare and the effects that this will have on people living in different areas. 

The award will involve work with communities, local and national governments, and with other stakeholders to devise plans designed to encourage adaptation and preparedness. The research will work to determine the feasibility of climate risk insurance in assisting identified populations’ access to health services to address extreme weather-related health problems. Targeted financial support to facilities and staff will be provided. The project has five objectives:

1) To create a comprehensive overview of hazards posed by extreme weather events in a changing climate at the level of individual health facilities in Kenya and create methods to replicate this approach elsewhere. 

2) To explore the scale and impact of effects related to closure or limitations of health services due to extreme weather on vulnerable populations in Kenya and methods to replicate this approach elsewhere.
 
3) To determine the physical, operational, and workforce risks posed to health facilities by extreme weather and design new tools for analysing these risks. 

4) To explore how climate risks and their effect on health and health services can be conveyed to community members in Kenya and how their priorities can inform practical adaptive action to ensure local resilience of health facilities. 

5) To examine the economic impact of extreme weather events on the Kenyan population and on healthcare facilities and what climate risk strategies, including climate risk insurance, can be used to manage risks.
NIHR RIGHT 4: Preventing Deaths from Acute Poisoning in Low- and Middle-Income Countries A UK and low-and-middle-income-country (LMIC) research partnership that aims to prevent deaths from acute poisoning. The project team will work closely with the World Health Organization (WHO) to strengthen Poison Information Centres (PIC), develop global guidelines, and provide clinical/public health research training. Primary research will address two major global problems: methanol and occupational pesticide poisoning. Clinical research on novel methanol diagnostics will be performed in major hospitals in India and Bangladesh, while an anthropological study of pre-hospital treatment of pesticide poisoning will take place in Sri Lankan villages. This work is a collaboration between 17 professionals located in partner institutions in Bangladesh, Sri Lanka, India, Iran, South Africa, China, Australia, Denmark, Norway, and the UK. Capacity building for research and PIC development will be done in partnership with the Asia-Pacific Association of Medical Toxicology (APAMT) and the Middle-East and North Africa Clinical Toxicology Association (MENATOX). The work of this NIHR RIGHT4 award is essential because poisoning is a neglected problem that kills more than 300,000 people each year, many of them in LMICs. The WHO recognises the urgent need for better knowledge on how/where poisoning occurs, tools to diagnose or treat patients, and national standards/guidance. The Centre will directly address these issues. To improve the clinical care of patients with acute poisoning in low-and-middle-income countries (LMICs) by:
1) Testing the use and cost-effectiveness of a novel bed-side diagnostic method for methanol poisoning in two controlled clinical trials in India and Bangladeshi hospitals
2)Addressing community acceptance of antidotes for pesticide poisoning that could be given after poisoning but before the patient reaches hospital

To expand LMIC research on acute poisoning and global Poison Information Centre (PIC) capacity, through providing training at annual international clinical toxicology congresses in the Asia-Pacific and Middle-East/North African regions.

To create a global network of LMIC research centres of excellence on acute poisoning by increasing research capacity at sites in India, Bangladesh, and Sri Lanka.

Develop international guidance for management of pesticide poisoning and methanol poisoning, in collaboration with the World Health Organization.

Our overarching question is whether the individual research work programs, generation of international guidelines, and increase in research and PIC capacity, will result in substantially more patients receiving evidence-based treatment for poisoning across the world, especially in LMICs. For the two poisons we have highlighted (methanol, pesticides) primary research will develop new diagnostic and treatment options and deepen our understanding.
European and Developing Countries Clinical Trials Partnership (EDCTP) phase II:  Support for The GloPID-R Secretariat The UK Department of Health and Social Care (DHSC) funds outstanding global health research through the National Institute for Health and Care Research (NIHR). The NIHR provided funding to European and Developing Countries Clinical Trials Partnership (EDCTP) which aims to support collaborative research that accelerates the clinical development of new or improved interventions to prevent or treat poverty related as well as emerging and re-emerging infectious diseases affecting sub-Saharan Africa. NIHR has supported the research as part of the the Global Research Collaboration for Infectious Diseases Preparedness (GloPID-R) Secretariat on Pandemic Preparedness: Analytical Capacity and Funding Tracking programme (Pandemic PACT). This activity is a component of European and Developing Countries Clinical Trials Partnership (EDCTP) phase II programme (GB-GOV-10-EDCTP2). Support to develop the creation of Pandemic Analytical Capacity and Funding Tracking Programme (Pandemic PACT) database which build on the COVID CIRCLE research tracker established during the COVID-19 pandemic. Pandemic PACT will develop a research funding tracking and analysis capability for a range of emerging infections, in particular focussed on those primariliy affection low and middle-income country poulations, with the outputs linked to major funders, decision makers and WHO.